3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
9
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Rectal Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
10
Radiotherapy
4
Bevacizumab
4
etoposide phosphate
3
Surgical Procedures, Operative
3
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
3
Vorinostat
2
Perfusion Magnetic Resonance Imaging
2
O(6)-benzylguanine
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Gadolinium DTPA
2
Filgrastim
2
Erlotinib Hydrochloride
2
Dynamic Contrast Enhanced Magnetic Resonance Imaging
2
Dexamethasone
2
Congresses as Topic
2
Carboplatin
2
Calcium Dobesilate
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
vocimagene amiretrorepvec
1
varlilumab
1
transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38)
1
talampanel
1
sodium thiosulfate
1
selinexor
1
sargramostim
1
regadenoson
1
poly ICLC
1
plerixafor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Oligodendroglioma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts